

Special Issue

Neutralizing Antibody Response against SARS-CoV-2

Message from the Guest Editors

We look forward to your contributions, that include the virus neutralization data (live virus or surrogate assays) on sera samples from healthy/immune-compromised individuals with a background of vaccination against SARS-CoV-2, natural infection, or both. For your convenience, please find ' Research Interests here: : Infection and Immunity, Immunotherapy, Check-Point Inhibitors and Stimulators, T cell response against SARS-CoV-2, Viral Immunity, Translational Research, Clinical Trials, Bacterial and Viral Vaccines, Immune mechanism behind antivirals, host-pathogen immunology : vaccination against SARS-CoV-2; antiviral research; host-pathogen interaction

How we can have cooperation in the near future.

Guest Editors

Dr. Lalit Batra

1. Regional Biocontainment Lab (RBL), Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), University of Louisville, Louisville, KY 40222, USA; 2. Bioengineering Department, J.B. Speed School of Engineering, University of Louisville, Louisville, KY 40292, USA

Dr. Divyasha Saxena

Center for Predictive Medicine (CPM), Clinical Translational Research Building (CTRB), 505 South Hancock Street, Rm#626A, Louisville, KY 40222, USA

Deadline for manuscript submissions

closed (31 August 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/123963

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).